|
TORONTO, ONTARIO--(Marketwired - May 7, 2013) - Novadaq® Technologies Inc. ("Novadaq" or the "Company") (TSX:NDQ)(NASDAQ:NVDQ), a developer of clinically-relevant fluorescence imaging solutions for use in surgical and outpatient wound care procedures, announced today the closing of its previously announced sale of 3,900,000 common shares, on a bought deal basis, at a price to the public of $12.90 per common share, pursuant to an underwriting agreement with Canaccord Genuity Inc. Prior to the closing, Canaccord Genuity Inc. exercised in full the option to purchase an additional 585,000 common shares solely to cover over-allotments. |
